I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer

The FDA recently approved Lipfendra, an oral PCSK9 inhibitor from Merck designed to lower blood cholesterol. While many in the medical field label this a breakthrough, practicing cardiologists are noting that the reality for patients is more complex than the headlines suggest.

Historically, PCSK9 inhibitors required injections. An oral alternative marks a technical milestone, transitioning from lab research to clinical practice. New heart health guidelines support aggressive cholesterol management, which positions this drug as a potential option for high-risk individuals. However, the excitement surrounding the approval ignores significant barriers that remain before this becomes a standard treatment.

Dr. Vishal Khetpal, a preventive cardiologist, notes that clinical data regarding long-term cardiovascular outcomes for enlicitide are still pending. The current buzz around the drug reflects the intense attention economy within modern medicine, where new product launches often receive hype that outpaces established patient evidence.

Patients and providers must weigh the convenience of a pill against the lack of long-term data on actual heart disease prevention. While the science behind the drug is significant, the path to widespread clinical adoption remains uncertain. Decisions on whether to prescribe Lipfendra will depend on more than just the delivery method; it will depend on whether the drug provides genuine, measurable health benefits for the average patient.